RE:Mouse StudyOne of the significant findings of this MSS CRC study which was just published on October 25, 2022 is:
Reovirus and anti-PD-1 combination therapy synergistically enhances the anti-tumor adaptive immune response in CT26 mouse tumors which proved the authors hypothesis that a combination of reovirus with an ICI, such as an anti-PD-1, would have synergistic therapeutic efficacy against MSS type of CRC tumors.
They domonstrated that the antitumor activity of the drug combination is associated with the induction of apoptosis in tumor cells as well as immune activation in the microenvironment.
Therein the authors reported for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus to the therapeutic regimen - which certainly is a revelaltionary finding that will potentially have impact on how CRC can be treated using pelareorep + immune checkpoint inhibitors.